Technical Analysis for MESO - Mesoblast Limited

Grade Last Price % Change Price Change
grade D 5.1686 18.00% 0.79
MESO closed up 18.0 percent on Monday, March 18, 2019, on 7.25 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical MESO trend table...

Date Alert Name Type % Chg
Mar 18 Crossed Above 50 DMA Bullish 0.00%
Mar 18 MACD Bullish Centerline Cross Bullish 0.00%
Mar 18 180 Bullish Setup Bullish Swing Setup 0.00%
Mar 18 Expansion Breakout Bullish Swing Setup 0.00%
Mar 18 Expansion Pivot Buy Setup Bullish Swing Setup 0.00%
Mar 18 Pocket Pivot Bullish Swing Setup 0.00%
Mar 18 Volume Surge Other 0.00%
Mar 18 Wide Range Bar Range Expansion 0.00%
Mar 18 Above Upper BB Strength 0.00%
Mar 18 Gapped Up Strength 0.00%

Older signals for MESO ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative therapeutic cell-based products in Australia, the United States, and Singapore. The company is developing therapeutic products using its proprietary technology platforms, which include mesenchymal lineage adult stem cells (MLCs) to treat conditions with unmet medical needs, including cardiac diseases, spine and musculoskeletal disorders, oncology and hematology diseases, and immune-mediated and inflammatory conditions. Its lead product candidates comprise MPC-150-IM for congestive heart failures; MPC-06-ID to treat chronic lower back pain due to moderate degenerative disc diseases; MSC-100-IV for the treatment of steroid refractory acute graft versus host diseases (GVHDs); and MPC-300-IV for biologic refractory rheumatoid arthritis and diabetic nephropathy. The company is also developing JR-031 for pediatric and adult GVHDs; MPC-25-IC, which is in Phase II clinical trial to treat acute cardiac ischemia; MPC-25-Osteo that has been completed Phase II clinical trial for the treatment of spinal fusion; and MPC-CBE, which is in Phase III clinical trial to treat bone marrow transplantations. The company has strategic alliances with Lonza Group for clinical and long-term commercial production of its off-the-shelf adult stem cell products; and Teva Pharmaceutical Industries Ltd. for the development and commercialization of its MPCs for cardiovascular diseases and neurologic conditions. Mesoblast Limited was founded in 2004 and is headquartered in Melbourne, Australia.
Health Biotechnology Life Sciences Pharmaceutical Industry Stem Cells Therapeutic Products Cardiovascular Diseases Technology Platforms Diabetic Nephropathy Back Pain Mesoblast Regenerative Biomedicine Host Diseases
Is MESO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 8.78
52 Week Low 3.35
Average Volume 46,917
200-Day Moving Average 5.6039
50-Day Moving Average 4.483
20-Day Moving Average 4.3904
10-Day Moving Average 4.3919
Average True Range 0.2279
ADX 16.03
+DI 43.9365
-DI 10.923
Chandelier Exit (Long, 3 ATRs ) 4.5663
Chandelier Exit (Short, 3 ATRs ) 4.8337
Upper Bollinger Band 4.8338
Lower Bollinger Band 3.947
Percent B (%b) 1.38
BandWidth 20.198615
MACD Line 0.0457
MACD Signal Line -0.0164
MACD Histogram 0.0621
Fundamentals Value
Market Cap 439.05 Million
Num Shares 84.9 Million
EPS -0.97
Price-to-Earnings (P/E) Ratio -5.33
Price-to-Sales 193.69
Price-to-Book 0.90
PEG Ratio -0.30
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.08
Resistance 3 (R3) 6.01 5.63 5.93
Resistance 2 (R2) 5.63 5.40 5.67 5.88
Resistance 1 (R1) 5.40 5.25 5.51 5.47 5.83
Pivot Point 5.02 5.02 5.08 5.06 5.02
Support 1 (S1) 4.79 4.79 4.90 4.86 4.51
Support 2 (S2) 4.41 4.64 4.45 4.46
Support 3 (S3) 4.18 4.41 4.41
Support 4 (S4) 4.25